Bifidobacterium pseudocatenulatum INIA P815: The first bacterium able to produce urolithins A and B from ellagic acid

Gaya, Pilar; Peirotén, Ángela; Médina, Margarita; Álvarez, Inmaculada; Landete, José María

doi:10.1016/j.jff.2018.03.040

Cited by 76 publications

(60 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the production of other flavonoid aglycones has been observed, with an important role of B. breve and B. pseudocatenulatum strains. One of them, B. pseudocatenulatum INIA P815, which showed good levels of almost of the aglycones studied, had shown previously the ability to produce urolithins A and B that are phytoestrogens of interest in human health (Gaya, Peirotén et al , ).…”

Section: Discussionmentioning

confidence: 99%

Production of flavonoid and lignan aglycones from flaxseed and soy extracts by Bifidobacterium strains

Peirotén

Álvarez

Landete

2019

Int J of Food Sci Tech

Self Cite

View full text Add to dashboard Cite

Flaxseed and soybean are an important source of phytochemical compounds, mainly lignans and isoflavones, but also of flavones, flavanones and flavonols. These compounds appear mainly glycosylated in plant food and are converted into aglycones by the intestinal microbiota, increasing their bioavailability. In this work, we analyse the ability of Bifidobacterium strains (n = 25) to produce lignan and flavonoids aglycones from flaxseed and soybean extracts. Most of the Bifidobacterium strains increased the concentrations of secoisolariciresinol, daidzein, genistein, naringenin, eriodyctiol, luteolin and apigenin. Moreover, Bifidobacterium pseudocatenulatum and Bifidobacterium breve strains showed high production of herbacetin, increased the kaempferol concentration and produced quercetin and quercetagetin. B. pseudocatenulatum INIA P815 and B. breve INIA P367 produced 32.37 AE 2.81 and 28.64 AE 3.36 mg respectively of herbacetin g À1 of lignan extract. Bifidobacterium strains transformed the glycosides of a wide range of flavonoids into their aglycones, increasing the antioxidant activity and improving their bioavailability. Metabolism of flavonoids by bifidobacteria A. Peirot en et al. 2123 102.6 AE 57.6 139.4 AE 32.4 141.5 AE 21.7 B. pseudocatenulatum INIA P846 152.8 AE 22.1 158.4 AE 12.0 168.2 AE 18.8 B. pseudocatenulatum INIA P946 204.2 AE 35.3 154.8 AE 6.4 195.7 AE 11.1 B. pseudolongum INIA P2 13.6 AE 4.4 65.4 AE 2.3 73.2 AE 15.2 B. pseudolongum INIA P120 16.8 AE 7.5 46.7 AE 2.6 69.5 AE 11.7 B. pseudolongum INIA P977 15.8 AE 4.4 62.1 AE 16.9 101.6 AE 8.0 Metabolism of flavonoids by bifidobacteria A. Peirot en et al. †Units are expressed as equivalents of Trolox or Gallic acid expressed as mg mL À1 of fermentation media. Metabolism of flavonoids by bifidobacteriaA. Peirot en et al.

show abstract

Section: Discussionmentioning

confidence: 99%

Production of flavonoid and lignan aglycones from flaxseed and soy extracts by Bifidobacterium strains

Peirotén

Álvarez

Landete

2019

Int J of Food Sci Tech

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, by complexing EA with cyclodextrins, it is possible to enhance EA’s anti-inflammatory, antioxidant or even antimicrobial properties [ 111 , 114 ]. Additionally, the production of several urolithins, such as M5, M6, C, [ 116 ] isourolithin A [ 117 ] and urolithins A and B [ 118 ], has been described. The possibilities of such probiotics mitigate EA’s bioavailability limitations and bolster applications of EA in the development of functional foods and nutraceuticals.…”

Section: Bioavailability Of Ellagitannins and Ellagic Acidmentioning

confidence: 99%

Recent Advances in the Production and Applications of Ellagic Acid and Its Derivatives. A Review

2020

View full text Add to dashboard Cite

Ellagitannins (ETs), characterized by their diversity and chemical complexity, belong to the class of hydrolysable tannins that, via hydrolysis under acidic or alkaline conditions, can yield ellagic acid (EA). They are mostly found as a part of extractives in angiosperms. As known antioxidants and chelators, EA and EA derivatives are drawing an increasing interest towards extensive technical and biomedical applications. The latter ones include possible antibacterial, antifungal, antiviral, anti-inflammatory, hepato- and cardioprotective, chemopreventive, neuroprotective, anti-diabetic, gastroprotective, antihyperlipidemic, and antidepressant-like activities, among others. EA’s synthesis and production challenges prompt further research on new methods and alternative sources. Conventional and prospective methods and raw materials for the production of EA and its derivatives are reviewed. Among the potential sources of EA, the residues and industrial streams of the pulp industry have been highlighted and considered as an alluring alternative in terms of commercial exploitation.

show abstract

“…Three urolithin-producing bacteria from the human gut belonging to the genus Gordonibacter ( G. pamelaeae and G. urolithinfaciens ) and Ellagibacter isourolithinifaciens have been identified to correlate with metabotype A positively[ 13 ]. Recently, Gaya et al[ 14 ] have reported that also Bifidobacterium pseudocatenulatum strain can produce UA.…”

Section: Introductionmentioning

confidence: 99%

Potential of the ellagic acid-derived gut microbiota metabolite – Urolithin A in gastrointestinal protection

Kujawska

Jodynis‐Liebert

2020

WJG

View full text Add to dashboard Cite

Urolithin A (UA) is a metabolic compound generated during the biotransformation of ellagitannins by the intestinal bacteria. The physiologically relevant micromolar concentrations of UA, achieved in the plasma and gastrointestinal tract (GI) after consumption of its dietary precursors, have been revealed to offer GI protection. The health benefit has been demonstrated to be principally related to anticancer and anti-inflammatory effects. UA has been shown to possess the capability to regulate multiple tumor and inflammatory signaling pathways and to modulate enzyme activity, including those involved in carcinogen biotransformation and antioxidant defense. The purpose of this review is to gather evidence from both in vitro and in vivo studies showing the potential of UA in GI protection alongside suggested mechanisms by which UA can protect against cancer and inflammatory diseases of the digestive tract. The data presented herein, covering both studies on the pure compound and in vivo generated UA form its natural precursor, support the potential of this metabolite in treatment interventions against GI ailments.

show abstract

Bifidobacterium pseudocatenulatum INIA P815: The first bacterium able to produce urolithins A and B from ellagic acid

Cited by 76 publications

References 25 publications

Production of flavonoid and lignan aglycones from flaxseed and soy extracts by Bifidobacterium strains

Production of flavonoid and lignan aglycones from flaxseed and soy extracts by Bifidobacterium strains

Recent Advances in the Production and Applications of Ellagic Acid and Its Derivatives. A Review

Potential of the ellagic acid-derived gut microbiota metabolite – Urolithin A in gastrointestinal protection

Contact Info

Product

Resources

About